University of Sharjah May 14 2025 How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti- multiple myeloma (MM) drug, according to a new study published in the European Journal of Haematology. The study analyzed data from 1,804 patients enrolled in three large-scale clinical trials-MAIA, POLLUX, and CASTOR. Across these trials, the median patient age was 66 years, and 44% were female.